Gilead Sciences, through its Kite Pharma subsidiary, acquired Interius BioTherapeutics for $350 million, gaining access to single-shot in vivo CAR-T therapy technology aimed at simplifying cell engineering inside patients. This move joins other major acquisitions in the burgeoning in vivo gene and cell therapy space, promising broader accessibility to CAR-T treatments by bypassing complex ex vivo modification procedures. The acquisition supports Gilead’s strategic expansion in immuno-oncology.